402 results about "Mrna level" patented technology

Drug-naive and drug-free schizophrenic PBL were screened to identify additional markers that are differentially expressed compared to healthy individuals using microarray and quantitative real-time PCR (QRT-PCR) techniques. Genes for dopamine D₂ receptor (DRD2) and inwardly rectifying potassium channel (Kir2.3) were found to be overexpressed in microarray analysis. Increased mRNA levels were confirmed by QRT-PCR using SybrGreen method and dual labeled TaqMan probes.

The invention relates to a method for diagnosing schizophrenia in a subject comprising assessing the level or the expression level of at least one of the following genes or proteins: Kir2.3 or DRD2 or a gene encoding Kir2.3 or DRD2. The invention further relates to agents and uses thereof, said agents specifically binding to said proteins or nucleic acids encoding them, diagnostic kits and screening methods.

Use of both molecular markers allow prediction of schizophrenia and help to follow efficiency of drugs in therapy in order to provide a more tailored medication for schizophrenic patients.

The present invention provides for methods of quantitating the amounts of proteins or peptides, including those that are closely related isoforms, using matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). Measurement of protein concentrations in vivo has been extremely difficult and problematic, and protein concentrations have not been shown to correlate well with mRNA levels, the standard used in the past. The present invention overcomes the deficiencies of prior methodologies by taking advantage of MALDI-TOF-MS technology and applying it to proteins and peptides in a way that allows for accurate, quantitative measurement in vivo of protein or peptide concentrations.

The invention provides a set of highly orthogonal six-code universal sequences for use in bDNA singleplex and multiplex nucleic acid hybridization assays. The six-code orthogonal sequences do not cross-hybridize and thus, minimize or eliminate the 3-mer cross-hybridization inherent in the second and third generation bDNA assays. The highly orthogonal universal sequences may be used in singleplex or multiplex bDNA assays quantitatively and qualitatively to determine mRNA levels in a sample; to screen for and genotype targets, such as viruses, that are present in low volumes in a sample; to screen for and genotype SNPs; and to measure changes in the amount of a gene in a sample such as when gene amplifications or deletions occur. The highly orthogonal universal sequences may also be used as universal capture probes to selectively bind assay components in a way that facilitates their further analysis.

The invention provides the construction for a farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector, which comprises the following steps of: sieving the most effective target sequence of an FDS (farnesyl diphosphate synthase) gene RNAi (RNA interference) in a tool cell 293T cell, synthesizing the double-stranded DNA of the most effective target sequence, connecting to a pGCSIL-GFP vector and successfully constructing the recombinant vector through enzyme cutting, sequencing and identification. Researches indicate that the constructed RNA interference vector LV-sh-FDS can downwards modulate the expression of an FDS mRNA (Messenger RNA) level in a neonatal rat cardiac myocyte, simultaneously can downwards modulate the expression of myocardial hypertrophy markers such as cell areas and marker genes beta-MHC (Myosin Heavy Chain) and BNP (Brain Natriuretic Peptide), additionally can effectively inhabit the activity of RhoA while downwards modulating the FDS, can be applied in preparing medicaments for treating myocardial hypertrophy diseases and also can be applied in preparing medicaments for cholesterol metabolic control.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair ERCC1 and methods comprising their use for detecting levels of ERCC1 mRNA.

The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with mouth, gums and teeth. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity and reduces cytokine production at the mRNA level in normal, aged and damaged periodontal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the mouth, gums and teeth. The method for preventing and treating diseases and conditions of the mouth, teeth and gums is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria, Oroxylum, Acacia or Uncaria genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally the present invention provides a method for the prevention and treatment of diseases and conditions of the mouth, teeth or gums, including but not limited to periodontal diseases, such as gingivitis, periodontitis, pulpitis, periodontal conditions caused by the physical implantation of oral dentures, trauma, injuries, bruxism, neoplastic and other degenerative processes; material alba, pellicles, dental plagues, calculus, and stains. Use of the composition described herein also affords the benefit of maintaining optimum saliva production and pH, minimizing bacterial growth, reducing the formation of pellicles and plague, inhibiting tooth decalcification and tooth caries (decay), promoting remineralization, which yields healthy gums, whitening teeth, maintaining healthy oral hygiene and reducing oral malodour (halitosis).

The invention relates to bifidobacterium breve CCFM1025, a fermented food and application thereof. The bifidobacterium breve CCFM1025 can be used for improving the depression-like behavior of a depression mouse, improving 5-hydroxytryptamine in the brain of the depression mouse, improving the level of 5-hydroxytryptamine and a brain-derived neurotrophic factor, reducing the level of corticosteronein serum of the depression mouse, improving the level of 5-hydroxytryptamine in the serum of the depression mouse, improving intestinal flora disturbance of the depression mouse, reducing the abundance of intestinal veillonella, improving the abundance of bifidobacterium and mycoplasmataceae, improving alpha-diversity of intestinal flora and reducing occurrence of inflammatory bowel disease and obesity. By adopting the bifidobacterium breve CCFM1025, the mRNA level of tryptophan hydroxylase in a simulated entero-chromaffin cell can be improved, the secretion volume of 5-hydroxytryptophane ofthe cell can be improved, and a precursor substance is specifically provided to synthesis of 5-hydroxytryptamine in the brain. The bifidobacterium breve CCFM1025 has a wide application prospect.

The invention discloses a low-expression CYP7A1 hepatic cell and a constructing method thereof. A method for inhibiting the CYP7A1 expression level of the hepatic cell comprises the step of introducing an encoding gene of small-interference RNA which is used for inhibiting the CYP7A1 gene expression into the hepatic cell so as to inhibit the CYP7A1 expression level of the hepatic cell. A slow virus vector system can be used for introducing the encoding gene of small-interference RNA which is used for inhibiting the CYP7A1 gene expression into the hepatic cell. An experiment proves that the method of the invention can obviously regulate the expression level of the CYP7A1 gene of the hepatic cell in an mRNA level and a protein level downwards and can further effectively reduce the secretoryvolume of total bile acid. The Low-expression CYP7A1 hepatic cell and the constructing method thereof can be used for the fundamental research and the clinical application of biologic artificial liver supporting treatment and have a wide application prospect.

The invention discloses a kit for quantitatively detecting a BCR/ABL mRNA level. The kit comprises a standard product which is used for manufacturing a standard curve, an inner reference gene real-time quantitative PCR system and at least one of the following three real-time quantitative PCR systems: an M-type BCR/ABL real-time quantitative PCR system, m-type BCR/ABL real-time quantitative PCR system and a mu-type BCR/ABL real-time quantitative PCR system. The kit can accurately, quickly and quantitatively detect various BCR/ABL mRNA levels, is used for diagnosing chronic myelogenous leukemia and acute lymphoblastic leukemia expressed by BCR/ABL and monitoring minimal residual diseases in a treatment process, and provides an important molecular basis for accurate diagnosis of clinical diseases, determination of a treatment proposal, curative effect evaluation and prognosis.

The invention relates to a BCR/ABL fusion gene (P210bcr/abl) mRNA fluorescence quantitative PCR measurement detection reagent box which comprises lymphocyte segregating liquid, RNA extracting liquid A, RNA extracting liquid B, Oligo (dT) 12-18, RT reaction fluid, reverse transcriptase, quantitative PCR reaction fluid, standard sample, comparison sample, and DEPC water; wherein, a marked primer and a non-marked primer are contained in the quantitative PCR reaction fluid. The reagent box can accurately detect the BCR/ABL fusion gene (P210) mRNA level in the specimen to be detected by extracting the total RNA of medulla ossium or peripheral blood, obtaining cDNA through reverse transcriptase and being combined with a real-time fluorescence quantitative PCR measurement detection technology. The reagent box adopts the latest self-quenched probe technology, thereby having the advantages that the repetitiveness is good, the sensitivity is high, the cost is low, and the invention can be applied to the dynamic monitoring of chronic myelocytic leukemia diagnosis, curative effect observation, prognosis and micro residual leukemia (MRD).

A method is disclosed for individually tailoring the administration of dietary components such as supplements. In the method, whole blood of a mammal is exposed to a dietary component. The level of a marker mRNA linked to a disease state is measured in leukocytes after exposure to the dietary component, and in some cases after further stimulation of the exposed blood cells. By comparing the mRNA level after exposure with the value found in unexposed blood cells, it is possible to determine what the effect of the dietary component will be in the mammal. By screening blood of the mammal against a number of possible dietary components, it is possible to develop an optimized set of dietary components tailored to the specific mammal to treat or prevent a disease state.

The invention relates to preimplantation genetic diagnosis on an embryo by using new single cell nucleic acid amplification technology, which mainly utilizes the signal amplification action of the mRNA (messenger Ribose Nucleic Acid) to detect the multiplication or deletion of DNAs (Deoxyribonucleic Acids) of certain chromosome segments. According to the central dogma, the mRNA is transcribed by using the DNA as the template, the abnormity of the number of copies of the DNA template can cause the change of the quantity of the mRNAs; and in the transcription process, the multiplication or deletion of the DNA template can be amplified on the mRNA level, and can be easily detected. The main technical method is as follows: the single cell mRNA of a human embryo is subjected to PCR (Polymerase Chain Reaction) amplification after being subjected to reverse transcription and addition of a common primer; by using the amplification product as the template, quantitative PCR with a 96-pore plate is used for detecting the expression level of 8 genes of a single cell or a small amount of cells; and the detection result can be compared with a normal diploid embryo, so as to distinguish the embryo sex of X chromosome recessive inheritance family history, and the multiplication and deletion of Trisomy 21, Trisomy 18, Trisomy 13 and sex chromosome and carry out genetic diagnosis on some common chromosome anomalies.

The identification of mutations in NURR1 provides molecular tools for the development of diagnostic, prophylactic and therapeutic agents for Parkinson's Disease. In specific embodiments, two point mutations are identified in exon 1 of the NURR1 gene in 10/107 (9.3%) cases of familial Parkinson's disease (PD). The mutations reduce NURR1 gene expression (mRNA and protein levels) by 87–95% and decrease tyrosine hydroxylase (a rate-limited dopamine synthesis enzyme) gene expression in vitro. It is also demonstrated that in vivo NURR1 mRNA levels in the lymphocytes from the PD patients with the exon 1 mutation are reduced by 68–84%, and in over 50% sporadic PD patients the NURR1 mRNA levels in lymphocytes are significantly reduced. A homozygous polymorphism is identified in intron 6 of NURR1 that correlates with the presence of Parkinson's disease. A splicing variant in NURR1 exon 5 is identified.

The invention relates to a diagnostic marker for malignant glioma and belongs to the technical field of molecular biology. Particularly, the marker is an NES gene and an expression product thereof. The diagnostic marker has the advantages that comprehensive genomics and proteomics analysis is carried out on a GBM, and through gene expression analysis based on a gene chip and RNA sequencing and proteome analysis of LC/MS/MS, the mRNA level and protein level of the NES gene are regulated up. Through survival analysis on the NES, over-expression of the NES is related to poor prognosis of a GBM patient, so that the NES can be used as a GBM biomarker and a potential therapeutic target. The NES gene is used for encoding nestin protein, is mainly applied to nerve cell expression, and can be used as the GBM biomarker and the potential therapeutic target.

The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent.

A number of selected genes/gene products; Application of selected genes/gene products at mRNA or protein levels either singly or in combination; Application of selected genes/gene products at mRNA levels by any of the methods such as: Northern blotting, or reverse transcription and conventional PCR, or reverse transcription and quantitative real-time PCR or gene expression micro-arrays; Application of selected genes/gene products at protein levels by either Western Blotting, or immunohistochemistry, or ELISA or functional assays or gel electrophoretic separation followed by spectroscopic identification (proteamics); Application of selected genes/gene products at peptide levels derived from proteins and spectroscopic methods of identification; Detection of a hyperproliferative condition, a precancerous condition, a predisposition to develop hyperproliferative condition or cancer by applying any one of the selected genes either singly or in combination in breast tissue, breast fluid, breast cells, blood or any other tissues or cells of a mammal; Application of selected genes either singly or in combination with others for designing molecular therapeutic drugs to treat a hyperproliferative condition, a precancerous condition, or predisposition to develop hyperproliferative condition or cancer of the breast or any other tissue of a mammal; Application of selected genes either singly or in combination with others for following up of a therapeutic treatment to a hyperproliferative condition, or precancerous condition, or predisposition to a hyperproliferative condition, or cancer, of the breast or any other tissue of a mammal; Application of selected genes either singly or in combination with others for screening of therapeutic drugs to a hyperproliferative condition, or precancerous condition, or predisposition to a hyperproliferative condition, or cancer, of the breast or any other tissue of a mammal; and Application of selected genes either singly or in combination with others for designing vaccines to prevent a hyperproliferative condition, or precancerous condition, or predisposition to a hyperproliferative condition, or cancer, of the breast or any other tissue of a mammal.